Maged Zeineldin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Maged Zeineldin has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
- Alan K. Meeker
Johns Hopkins University School of Medicine, Baltimore, MD
31 shared publications - Beisi Xu
Center for Applied Bioinformatics, St. Jude Children’s Research Hospital, Memphis, TN 38105, USA
31 shared publications - Christine Davis
Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland
31 shared publications - Christopher M. Heaphy
Department of Medicine, Section of Hematology-Medical Oncology, Boston University Chobanian & Avedisian School of Medicine, Boston Medical Center, Boston, MA
31 shared publications - Michael A. Dyer
St. Jude Children's Research Hospital
31 shared publications - Mindy Kim Graham
Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA
31 shared publications
Latest Publications
- Open Access
- 1 June 2026
- Published by Elsevier in Cancer Genetics
- Vol. 306-307, 69-90
Acquired ring chromosomes in hematological malignancies: A systematic evidence review for diagnostic advances, cytogenomic insights, and clinical significance by an International Consortium on Human Ring Chromosomes (ICHRC) working group
- 1 June 2026
- Published by Elsevier in Cancer Genetics
- Vol. 306-307, 69-90
Open AccessAcquired ring chromosomes in hematological malignancies: A systematic evidence review for diagnostic advances, cytogenomic insights, and clinical significance by an International Consortium on Human Ring Chromosomes (ICHRC) working group
- Open Access
Cell Ploidy Modulates Nucleolar Size via Dosage of Nucleolar Organizing Regions
Abnormal nucleolar morphology is a pathognomonic histologic feature of cancer cells. Nucleoli are biomolecular condensates and cytogenetic entities that form around nucleolar organizing regions (NORs), located on the short arms of acrocentric chromosomes. Given that aneuploidy is pervasive in human cancers and can involve NOR-bearing chromosomes, we investigated how aneuploidy-driven changes in NOR dosage impact nucleolar morphology. We used reversine, a spindle assembly checkpoint inhibitor, to induce chromosomal instability and complex aneuploidy in DLD1 colorectal cancer cells (near-euploid) and normal human colon organoids (colonoids, euploid). High resolution 3D imaging and quantitative analyses of reversine-treated cells showed overall doubling of total nucleolar volume per nucleus. Reversine-associated nucleolar enlargement occurred independently of global protein synthesis, and thus was not solely driven by increases in biosynthetic demand. The volume of individual nucleoli showed a direct linear correlation with the number of associated NORs, as revealed by 3D co-localization with NOR-specific FISH probes. These findings establish NOR dosage as a determinant of nucleolar morphology and metric of genomic instability, providing a new paradigm by which aneuploidy can modulate spatial chromosomal constraints and nuclear architecture in cancer. Significance statement: Cancer cells often show enlarged and abnormal nucleoli. We show that aneuploidy, a common feature of cancer, can directly reshape nucleolar morphology by altering the copy number of acrocentric chromosomal regions around which nucleoli form, NORs. Using high-resolution 3D imaging in cell lines and patient-derived colonoids, we find that nucleolar number and volume directly correlate with NOR number, independent of overall protein synthesis. Individual nucleolar volume scales with the number of 3D NOR associations, and prominent single nucleoli arise when NORs accumulate. These results provide evidence that aneuploidy can lead to aberrant nucleolar morphologies seen in many human cancers.
Open AccessCell Ploidy Modulates Nucleolar Size via Dosage of Nucleolar Organizing Regions
Abnormal nucleolar morphology is a pathognomonic histologic feature of cancer cells. Nucleoli are biomolecular condensates and cytogenetic entities that form around nucleolar organizing regions (NORs), located on the short arms of acrocentric chromosomes. Given that aneuploidy is pervasive in human cancers and can involve NOR-bearing chromosomes, we investigated how aneuploidy-driven changes in NOR dosage impact nucleolar morphology. We used reversine, a spindle assembly checkpoint inhibitor, to induce chromosomal instability and complex aneuploidy in DLD1 colorectal cancer cells (near-euploid) and normal human colon organoids (colonoids, euploid). High resolution 3D imaging and quantitative analyses of reversine-treated cells showed overall doubling of total nucleolar volume per nucleus. Reversine-associated nucleolar enlargement occurred independently of global protein synthesis, and thus was not solely driven by increases in biosynthetic demand. The volume of individual nucleoli showed a direct linear correlation with the number of associated NORs, as revealed by 3D co-localization with NOR-specific FISH probes. These findings establish NOR dosage as a determinant of nucleolar morphology and metric of genomic instability, providing a new paradigm by which aneuploidy can modulate spatial chromosomal constraints and nuclear architecture in cancer. Significance statement: Cancer cells often show enlarged and abnormal nucleoli. We show that aneuploidy, a common feature of cancer, can directly reshape nucleolar morphology by altering the copy number of acrocentric chromosomal regions around which nucleoli form, NORs. Using high-resolution 3D imaging in cell lines and patient-derived colonoids, we find that nucleolar number and volume directly correlate with NOR number, independent of overall protein synthesis. Individual nucleolar volume scales with the number of 3D NOR associations, and prominent single nucleoli arise when NORs accumulate. These results provide evidence that aneuploidy can lead to aberrant nucleolar morphologies seen in many human cancers.
- Open Access
- 20 June 2024
- Published by American Association for Cancer Research (AACR)
FIGURE 4 from The TERT Promoter is Polycomb-Repressed in Neuroblastoma Cells with Long Telomeres
TERT is a bona fide MYCN target. A, Alignments of DNA methylation from WGBS and MYCN-ChIP-seq in three MYCN-amplified neuroblastoma O-PDX models and cell line (SKNBE2) showing that MYCN binding overlaps with the hypomethylated region in the TERT promoter. The core promoter is shaded in red and THOR is shaded in yellow. B, Western blot analysis for MYCN and GAPDH (loading control) in different indicated doxycycline-inducible engineered cell lines to ectopically express MYCN in non–MYCN-amplified cells (left) or to express three different MYCN-shRNAs (indicated as A, B, C) in MYCN-amplified neuroblastoma cells (right). Relative MYCN band intensities in cells expressing MYCN-shRNA are indicated on top of the blots. C, A schematic representation of Luciferase reporter construct. The long construct contains the luciferase gene, and the TERT promoter core and THOR sequences, while the short construct does not contain the THOR promoter sequence. D, Fold change of Luciferase luminescence for the short construct (top) and the long construct (bottom) compared with control vehicle-treated controls. E, Fold change of TERT expression in the same cells measured by qRT-PCR. *, P < 0.05, error bars represent SD.
- 20 June 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFIGURE 4 from The TERT Promoter is Polycomb-Repressed in Neuroblastoma Cells with Long Telomeres
TERT is a bona fide MYCN target. A, Alignments of DNA methylation from WGBS and MYCN-ChIP-seq in three MYCN-amplified neuroblastoma O-PDX models and cell line (SKNBE2) showing that MYCN binding overlaps with the hypomethylated region in the TERT promoter. The core promoter is shaded in red and THOR is shaded in yellow. B, Western blot analysis for MYCN and GAPDH (loading control) in different indicated doxycycline-inducible engineered cell lines to ectopically express MYCN in non–MYCN-amplified cells (left) or to express three different MYCN-shRNAs (indicated as A, B, C) in MYCN-amplified neuroblastoma cells (right). Relative MYCN band intensities in cells expressing MYCN-shRNA are indicated on top of the blots. C, A schematic representation of Luciferase reporter construct. The long construct contains the luciferase gene, and the TERT promoter core and THOR sequences, while the short construct does not contain the THOR promoter sequence. D, Fold change of Luciferase luminescence for the short construct (top) and the long construct (bottom) compared with control vehicle-treated controls. E, Fold change of TERT expression in the same cells measured by qRT-PCR. *, P < 0.05, error bars represent SD.
- Open Access
- 20 June 2024
- Published by American Association for Cancer Research (AACR)
FIGURE 2 from The TERT Promoter is Polycomb-Repressed in Neuroblastoma Cells with Long Telomeres
Molecular characterization of telomere maintenance in neuroblastoma cell lines. Telomere maintenance mechanism was assessed in eight neuroblastoma cell lines used in this study: MYCN-amplified (NB5, SKNBE2, IMR32), moderate level of MYCN without amplification (NBL-S), ATRX-mutant (SKNMM, CHLA90), low-DAXX (SKNFI) and ever-shorter telomere (LAN6) neuroblastoma cells. A, Representative images of Telomere FISH (green) showing brighter signal in cell lines with long telomeres. B, Telomeric repeats in neuroblastoma cell lines relative to those in the telomerase-positive 293T cells using qPCR. Telomerase-negative, ALT-positive U2OS cells were used as a positive control for long telomeres. C, Representative blot of C-circle assay. U2OS cells were used as a positive control and PC3 cells were used as a negative control. The amount of DNA in nanograms (ng) is indicated on the blot. All reactions were done in the presence or absence of the Phi 29 (Phi) DNA polymerase. qRT-PCR was performed in neuroblastoma cell lines to measure TERT (D) and TERC (E) expression relative to the telomerase-positive 293T cell line. Gene expression was normalized to HPRT expression. The U2OS cell line was used as an ALT-positive control and does not express TERC.
- 20 June 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFIGURE 2 from The TERT Promoter is Polycomb-Repressed in Neuroblastoma Cells with Long Telomeres
Molecular characterization of telomere maintenance in neuroblastoma cell lines. Telomere maintenance mechanism was assessed in eight neuroblastoma cell lines used in this study: MYCN-amplified (NB5, SKNBE2, IMR32), moderate level of MYCN without amplification (NBL-S), ATRX-mutant (SKNMM, CHLA90), low-DAXX (SKNFI) and ever-shorter telomere (LAN6) neuroblastoma cells. A, Representative images of Telomere FISH (green) showing brighter signal in cell lines with long telomeres. B, Telomeric repeats in neuroblastoma cell lines relative to those in the telomerase-positive 293T cells using qPCR. Telomerase-negative, ALT-positive U2OS cells were used as a positive control for long telomeres. C, Representative blot of C-circle assay. U2OS cells were used as a positive control and PC3 cells were used as a negative control. The amount of DNA in nanograms (ng) is indicated on the blot. All reactions were done in the presence or absence of the Phi 29 (Phi) DNA polymerase. qRT-PCR was performed in neuroblastoma cell lines to measure TERT (D) and TERC (E) expression relative to the telomerase-positive 293T cell line. Gene expression was normalized to HPRT expression. The U2OS cell line was used as an ALT-positive control and does not express TERC.
- Open Access
- 20 June 2024
- Published by American Association for Cancer Research (AACR)
FIGURE 1 from The TERT Promoter is Polycomb-Repressed in Neuroblastoma Cells with Long Telomeres
DNA hypomethylation of the TERT locus in neuroblastoma cell lines, tumors and O-PDX. A, Alignments of DNA methylation from WGBS for the TERT locus in neuroblastoma cell lines (black), autopsy (red), and O-PDX (blue). Tumor autopsies and O-PDX that are derived from the same patients are connected by a curved line. The hypomethylated region shaded in gray starts −694 bases from the TERT TSS and ends 758 bases after the TSS.
- 20 June 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFIGURE 1 from The TERT Promoter is Polycomb-Repressed in Neuroblastoma Cells with Long Telomeres
DNA hypomethylation of the TERT locus in neuroblastoma cell lines, tumors and O-PDX. A, Alignments of DNA methylation from WGBS for the TERT locus in neuroblastoma cell lines (black), autopsy (red), and O-PDX (blue). Tumor autopsies and O-PDX that are derived from the same patients are connected by a curved line. The hypomethylated region shaded in gray starts −694 bases from the TERT TSS and ends 758 bases after the TSS.